Lymphopenia

Peripheral blood absolute lymphocyte count at diagnosis is an effective biomarker that can be used to risk-stratify patients with multiple myeloma, according to retrospective study results.

Low levels of lymphocytes in the blood could indicate an increased risk for death, according to a study published in CMAJ.

Daily treatment with mavorixafor improved outcomes among patients with warts, hypogammaglobulinemia, infections and myelokathexis, or WHIM syndrome, in the 4WHIM phase 3 clinical trial, according to the drug’s developer, X4 Pharmaceuticals.

Primary care patients with a low lymphocyte count “years before” developing pneumonia were at an increased risk for dying, researchers of a retrospective cohort study wrote in the British Journal of General Practice.

Pembrolizumab in combination with radiotherapy conferred promising survival outcomes with acceptable toxicity among patients with locally advanced head and neck squamous cell carcinoma, according to results of a single-arm phase 2 study presented at Multidisciplinary Head and Neck Cancers Symposium.

Concomitant steroid-pulse treatment and baseline lymphopenia were among risk factors for pneumocystis pneumonia among a cohort of patients with rheumatic diseases receiving steroid treatment, according to findings published in Arthritis Research & Therapy.